Many plateaus break spontaneously without dose changes
Specific Populations No clinically significant differences in semaglutide pharmacokinetics were observed based on age (18 years old), sex, race (White, Asian or Black or African American), ethnicity, body weight (40 to 188 kg), upper GI disease (i.e., chronic gastritis and/or gastroesophageal reflux disease), hepatic impairment (i.e., mild, moderate, severe based on the Child-Pugh system) and renal impairment (i.e., mild, moderate, severe, end staged renal disease)
The aggressive marketing is starting to draw the ire of regulators
Studies on free radicals, antioxidants, and co-factors
These products may be sold as dietary supplements or prescribed medicines, and they are intended for different situations